ABT

Abbott Laboratories 10-Q Summary: Period Ended September 30, 1998

Business Context and Reporting Period

This is an unaudited quarterly report (Form 10-Q) for Abbott Laboratories, an Illinois corporation, covering the three and nine months ended September 30, 1998. The company operates primarily in pharmaceutical, nutritional, hospital, and laboratory products. As of October 31, 1998, there were approximately 1.52 billion common shares outstanding. The financial statements reflect a two-for-one stock split approved in February 1998 and executed in May 1998.

Key Financial Metrics

Note: Debt figures represent the sum of short-term borrowings/current portion of long-term debt and long-term debt as of September 30, 1998 ($1,419.97M + $1,340.845M) and December 31, 1997 ($1,781.352M + $937.983M).

Material Changes vs. Prior Period

• Sales Growth: Net sales increased 6.0% in Q3 and 4.4% year-to-date (YTD) compared to 1997. Excluding the negative impact of a stronger U.S. dollar, sales growth was 9.3% in Q3 and 7.7% YTD.
• Profitability: Net earnings rose 12.8% in Q3 and 11.7% YTD. Diluted earnings per share increased 13.3% in Q3 and 13.4% YTD.
• Margins: Gross profit margin for Q3 1998 was 54.7%, down from 56.7% in Q3 1997, primarily due to the stronger U.S. dollar. YTD gross margin remained flat at 56.8%.
• Expenses: Research and development (R&D) expenses decreased as a percentage of sales to 9.6% in 1998 from 11.4% in Q3 1997. Selling, general, and administrative (SG&A) expenses decreased 1.5% in Q3 but increased 2.4% YTD, driven by inflation and marketing support for new products.
• Acquisitions: The company acquired International Murex Technologies Corporation for approximately $234 million in cash in April 1998.

Outlook, Risks, and Unusual Items

• Manufacturing Issues: The company announced manufacturing difficulties with the capsule formulation of its protease inhibitor, Norvir, in July 1998. This has resulted in supply shortages. The company plans to supply the liquid formulation as an alternative. While $197.0 million in Norvir sales were recorded YTD, the future impact on sales is unquantifiable.
• Litigation: A federal court approved a $57 million settlement for an independent retail pharmacy class action lawsuit on September 9, 1998. The company faces numerous other antitrust suits and patent challenges (e.g., terazosin hydrochloride patents ruled invalid in September 1998, currently under appeal). Management believes these will not have a material adverse effect.
• Liquidity: The company maintains AAA (S&P) and Aa1 (Moody's) credit ratings with $2.505 billion in unused domestic lines of credit. It issued $400 million in long-term debt YTD and has authorization to issue up to $750 million more.
• Share Repurchases: The company purchased and retired 17.25 million shares at a cost of $673.7 million during the first nine months of 1998. An additional 10.15 million shares remain authorized for purchase.
• Regulatory & External Risks: The company faces potential legislative changes regarding healthcare pricing and delivery. It is also managing Year 2000 (Y2K) remediation and Euro currency conversion preparations, estimating costs as immaterial to financial results.

Investor Verification Checklist

• Verify the extent of the Norvir capsule supply shortage and the timeline for resolution or full transition to liquid formulation.
• Monitor the status of the appealed patent invalidity rulings regarding terazosin hydrochloride and the remaining antitrust litigation.
• Assess the impact of the stronger U.S. dollar on future international sales growth, which was negatively affected by 8.7% in Q3.
• Review the progress of the $57 million litigation settlement and any potential additional legal reserves required.
• Confirm the company's ability to maintain its high credit ratings given the increase in total debt to fund acquisitions and operations.